Retension Pharmaceuticals Files 25-MB S-1/A Amendment
Retension Pharmaceuticals, Inc. filed a 25-MB S-1/A amendment with the SEC on October 5, 2026 — among the largest IPO filings of the day. The size reflects extensive clinical trial data, IP valuation disclosures, and R&D capitalization accounting.
51CFO view：A 25-MB S-1/A signals deep R&D accounting complexity: CFO must own clinical-stage expense capitalization, intangible asset amortization modeling, FDA pathway risk quantification, and SOX 404 controls over R&D spend.
Retension Pharmaceuticals, Inc. filed a 25-MB S-1/A amendment with the SEC on October 5, 2026 — among the largest IPO filings of the day. The size reflects extensive clinical trial data, IP valuation disclosures, and R&D capitalization accounting.
Source：SEC EDGAR · S-1 招股书备案